Swiss National Bank Bellus Health Inc. Transaction History

Swiss National Bank

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$7.14 - $8.53 $116,382 - $139,039	-16,300 Reduced 8.38%	178,100 $1.28 Million
Q4 2022 Feb 08, 2023	BUY	$8.22 - $10.76 $22,194 - $29,052	2,700 Added 1.41%	194,400 $1.6 Million
Q3 2022 Nov 09, 2022	BUY	$8.95 - $12.0 $468,084 - $627,600	52,300 Added 37.52%	191,700 $2.04 Million
Q2 2022 Aug 09, 2022	BUY	$6.46 - $10.02 $900,524 - $1.4 Million	139,400 New	139,400 $1.28 Million
Q4 2020 Feb 05, 2021	SELL	$2.27 - $3.3 $218,147 - $317,130	-96,100 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$2.14 - $12.02 $19,046 - $106,978	8,900 Added 10.21%	96,100 $218,000
Q2 2020 Aug 05, 2020	BUY	$8.88 - $11.15 $774,336 - $972,280	87,200 New	87,200 $896,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.